National Jewish Health is a 501(c)(3) organization based in Denver, Colorado, registered in 1979, with $401,084,397 in FY2023 revenue. CharityIndex grades it A, and it directs about 89% of spending to programs.
Revenue (FY2023)
$401.1M
▲ 15.1% vs prior year
Health median: $840K
Expenses (FY2023)
$399.1M
Net assets
$268.1M
Employees
2,081
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For National Jewish Health: 89% to programs · $11 to raise $100 earns a A on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For National Jewish Health: 8 mo reserves · +0% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For National Jewish Health: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For National Jewish Health: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
National jewish health's mission since 1899 is to heal, discover and educate as a preeminent healthcare institution. we serve by providing the best integrated and innovative care for patients and their families; by understanding and finding cures for the diseases we research; and, by educating and training the next generation of healthcare professionals to be leaders in medicine and science.
National jewish health receives various types of grants. in addition to the above, national jewish health received $54,909,280 of funding through grants which are included in part viii (revenues), lines 1e and 1f. national jewish health conducts extensive basic, translational and clinical biomedical research. in addition to translational research programs in its areas of clinical specialties, national jewish health conducts research in basic immunology, genetics, proteomics, cell biology, signal transduction, structural biology, cancer biology, and oxidant biology. research activities have resulted in a number of scientific discoveries that have improved care for patients worldwide. national jewish received a federal contract renewal to continue funding our copdgene research and network. funds for national jewish health's research are provided by grants from private and governmental agencies which include the national institute of health (nih), the department of defense (dod), national science foundation (nsf) and charitable contributions from private industry.
National jewish health is the nations' largest nonprofit provider of telephonic and technology-based commercial tobacco cessation services, delivering evidence-based, personalized telephone and online coaching programs in 23 states and for more than 80 health plans employer groups and wellness companies. the state grant contract revenue of $15,850,170 is included in part viii, line 1e, while the rest of the revenue is reported in section 4c above. since the development of our quitline program in 2002, national jewish health has assisted more than 2.5 million people with their quit attempts. national jewish health leverages emerging research and some of the industry's most prominent thinkers to continually adapt and improve our program in order to meet the needs of our clients and participants. the quitline program follows the best practices and industry standards published by the centers for diseases control and prevention (cdc) and north american quitline consortium (naqc). national jewish health's protocols are research- and evidence -based. the quitline is staffed by more than 80 professionals who are devoted to commercial tobacco use prevention and cessation. the tobacco cessation coaches (coaches) undergo rigorous training that enables them to tailor their coaching services based on participant needs using our proven-successful coaching model. for each person who reaches out to the quitline for help, the coaches immediately engage them in their quit journey to foster success, and our results demonstrate our proven track record. our surveys, conducted by an independent third party, show that individuals who receive our evidence-based coaching services and use cessation medications have a 37% long-term quit rate, one of the best quit rates in the nation.
National jewish health provides other programs and services such as professional education for medical professionals, specialized physicians services to local hospitals, and shares its expertise regarding specialized diagnostic techniques and treatment protocols with other partners and respiratory institutes.
Revenue grew from $225.7M (FY2013) to $401.1M (FY2023) across 11 reported years.
Financial snapshot
Operating margin
0.5%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$414.0M
Total liabilities
$146.0M
Net assets
$268.1M
Salaries & benefits
$192.4M
48% of expenses
Board members
45
44 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2023 | $401,084,397▲15.1% | $399,121,001▲7.9% | $268,051,000▲1.4% | $414,028,000▼0.7% | 990 |
| 2022 | $348,531,726▼2.7% | $370,065,540▲6.8% | $264,331,000▼5.6% | $417,131,000▼4.8% | 990 |
| 2021 | $358,276,772▼5.0% | $346,514,824▲1.5% | $280,044,000▼4.4% | $438,155,000▼3.5% | 990 |
| 2020 | $377,230,660▲13.8% | $341,524,571▲8.8% | $292,848,000▲22.5% | $453,973,000▲29.7% | 990 |
| 2019 | $331,534,080▲11.2% | $313,987,559▲10.5% | $239,153,000▲5.4% | $349,926,000▲15.0% | 990 |
| 2018 | $298,202,040▲7.2% | $284,109,927▲8.7% | $226,804,000▲6.1% | $304,229,000▲0.8% | 990 |
| 2017 | $278,258,147▲10.9% | $261,433,024▲4.0% | $213,793,000▲8.6% | $301,872,000▲3.4% | 990 |
| 2016 | $250,924,859▲0.2% | $251,277,238▲4.0% | $196,850,000▲3.8% | $291,957,000▲4.7% | 990 |
| 2015 | $250,332,189▲2.6% | $241,608,275▲3.5% | $189,626,000▲0.1% | $278,746,000▼0.3% | 990 |
| 2014 | $243,928,631▲8.1% | $233,336,396▲6.2% | $189,389,000▲0.8% | $279,558,000▼0.5% | 990 |
| 2013 | $225,725,956 | $219,793,392▲4.8% | $187,910,000▲6.6% | $280,920,000▲1.9% | 990 |
| 2012 | — | $209,781,870▲1.0% | $176,308,000▲3.7% | $275,571,000▲3.3% | 990 |
| 2011 | — | $207,666,858▲0.8% | $170,017,000▼2.9% | $266,823,000▲0.3% | 990 |
| 2010 | — | $206,070,886▲8.2% | $175,024,000▲12.0% | $265,935,000▲11.2% | 990 |
| 2009 | — | $190,524,428 | $156,334,000 | $239,210,000 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Michael S Salem Md — $2,347,443 (0.59% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Michael S Salem Md | President and Ceo, Bod Member | 50 | $2,347,443 |
| Gregory Downey Md | Evp Academic Affairs & Provost | 50 | $857,892 |
| Rao Mushtaq Md | Assistant Professor, Division of Oncology | 50 | $773,020 |
| Jeffrey King Md | Chief, Division of Gastroenterology | 50 | $723,116 |
| Pranav Periyalwar Md | Assistant Professor, Division of Gastroenterology | 50 | $665,897 |
| Christine K Forkner | Evp Corproate Affairs and Cfo, Ass't Treasurer | 50 | $639,822 |
| Stephen Frankel Md | Evp Clincial Affairs & Cco | 50 | $612,085 |
| Glenn Hirsch Md | Chief, Division of Cardiology | 50 | $568,430 |
| Kevin K Brown Md | Chair, Department of Medicine | 50 | $547,997 |
| Raphael Sung Md | Associate Professor, Division of Cardiology | 50 | $506,051 |
| Pamela L Zeitlin Md Phd | Chair, Department of Pediatrics | 50 | $485,182 |
| Lisa Tadiri | Vice President Development | 50 | $453,910 |
| Irina Petrache Md | Chief, Division Pulmonology | 50 | $433,600 |
| Carrie A Horn Md | Chief Medical Officer | 50 | $402,426 |
| Kristi Melton | Vp Clinical Business Operations | 50 | $368,542 |
| Seth Kligerman Md | Chair, Department of Radiology | 50 | $366,061 |
| Philippa Marrack Phd | Chair, Department of Immunology and Genomic Medicine | 50 | $257,418 |
| Debra Dyer Md | Professor, Department of Radiology | 50 | $219,567 |
| A Barry Hirschfeld | Lifetime Member, Bod | 2 | — |
| Blair E Richardson | Member, Bod | 2 | — |
| Contractor | Services | Paid |
|---|---|---|
| Rescue Agency Public Benefit LLC | Advertising & Professional Services | $1,414,000 |
| Health Systems Informatics Inc | Consulting & Data Conversion | $1,181,198 |
| Guidehouse Inc | Consulting | $782,158 |
| Usacs of Colorado Inc | Medical Provider Contracting | $779,167 |
| Bc Services | Professional Collections | $710,211 |
504 grants to National Jewish Health totaling $70.7M, reported by foundations on their Schedule I filings — showing the 15 most recent.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| Cystic Fibrosis Foundation | Clinical research study | 2024 | $1,170,525 |
| Gs Donor Advised Philanthropy Fund For Wealth Management Inc | Medical / public services | 2024 | $1,002,500 |
| Cystic Fibrosis Foundation | Clinical research center | 2024 | $618,968 |
| Cystic Fibrosis Foundation | Cf care center | 2024 | $468,421 |
| Cystic Fibrosis Foundation | Clinical research | 2024 | $392,074 |
| American Lung Association | Research | 2024 | $288,015 |
| Oregon Community Foundation | Physical health | 2024 | $237,125 |
| American Heart Association Inc | Research | 2024 | $156,640 |
| Cystic Fibrosis Foundation | Research | 2024 | $155,970 |
| American Endowment Foundation | Health, general | 2024 | $125,600 |
| Cystic Fibrosis Foundation | Pilot study | 2024 | $111,627 |
| Morgan Stanley Global Impact Funding Trust Inc | Unrestricted general support | 2024 | $105,000 |
| Denver Foundation | Health care n.e.c. | 2024 | $77,549 |
| Cystic Fibrosis Foundation | Research study | 2024 | $76,000 |
| Rose Community Foundation | Indoor air quality research, pediatric food allergy research, event support | 2024 | $70,680 |
Explore more
Data for National Jewish Health (EIN 74-2044647) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.